KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Current Assets (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Current Assets for 16 consecutive years, with $61.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 37.52% to $61.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.1 million through Dec 2025, down 37.52% year-over-year, with the annual reading at $61.1 million for FY2025, 37.52% down from the prior year.
  • Current Assets hit $61.1 million in Q4 2025 for Inovio Pharmaceuticals, up from $55.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $588.4 million in Q1 2021 to a low of $52.7 million in Q2 2025.
  • Historically, Current Assets has averaged $248.6 million across 5 years, with a median of $189.0 million in 2023.
  • Biggest five-year swings in Current Assets: surged 113.55% in 2021 and later tumbled 55.17% in 2025.
  • Year by year, Current Assets stood at $448.4 million in 2021, then decreased by 29.7% to $315.2 million in 2022, then crashed by 51.43% to $153.1 million in 2023, then crashed by 36.11% to $97.8 million in 2024, then tumbled by 37.52% to $61.1 million in 2025.
  • Business Quant data shows Current Assets for INO at $61.1 million in Q4 2025, $55.2 million in Q3 2025, and $52.7 million in Q2 2025.